|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
SCIDIR_ocn967096624 |
| 003 |
OCoLC |
| 005 |
20231120112202.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
161219s2017 ne ob 001 0 eng d |
| 040 |
|
|
|a IDEBK
|b eng
|e rda
|e pn
|c IDEBK
|d EBLCP
|d N$T
|d YDX
|d IDEBK
|d OPELS
|d N$T
|d OCLCF
|d UPM
|d MERER
|d OCLCQ
|d OTZ
|d OCLCO
|d OCLCQ
|d OCLCO
|d D6H
|d U3W
|d UKMGB
|d WYU
|d OCLCO
|d OCLCA
|d LQU
|d OCLCQ
|d S2H
|d OCLCO
|d LVT
|d VT2
|d OCLCO
|d OCLCQ
|d SFB
|d OCLCQ
|
| 015 |
|
|
|a GBB712283
|2 bnb
|
| 016 |
7 |
|
|a 018161795
|2 Uk
|
| 019 |
|
|
|a 966429067
|a 966899881
|a 1066636996
|a 1105182064
|a 1105569824
|a 1229757021
|a 1235822256
|
| 020 |
|
|
|a 032341737X
|q (ebk)
|
| 020 |
|
|
|a 9780323417372
|q (electronic bk.)
|
| 020 |
|
|
|z 9780323416252
|
| 020 |
|
|
|z 032341625X
|
| 035 |
|
|
|a (OCoLC)967096624
|z (OCoLC)966429067
|z (OCoLC)966899881
|z (OCoLC)1066636996
|z (OCoLC)1105182064
|z (OCoLC)1105569824
|z (OCoLC)1229757021
|z (OCoLC)1235822256
|
| 050 |
|
4 |
|a RM267
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.329
|2 23
|
| 245 |
0 |
0 |
|a Functionalized Nanomaterials for the Management of Microbial Infection :
|b a Strategy to Address Microbial Drug Resistance /
|c edited by Rabah Boukherroub, Sabine Szunerits, Djamel Drider.
|
| 264 |
|
1 |
|a Amsterdam :
|b Elsevier,
|c 2017.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Micro & nano technologies series
|
| 505 |
0 |
|
|a Front Cover; Functionalized Nanomaterials for the Management of Microbial Infection; Copyright Page; Contents; List of Contributors; Preface; 1 Resistance to Antibiotics and Antimicrobial Peptides: A Need of Novel Technology to Tackle This Phenomenon; 1.1 Resistance to Antibiotics; 1.2 Resistance to Bacteriocins Produced by Gram-Positive Bacteria (GPB); 1.3 Conclusion and Prospects; Acknowledgments; References; 2 The Role of the Food Chain in the Spread of Antimicrobial Resistance (AMR); 2.1 Introduction; 2.2 AMR in Foodborne Pathogenic Bacteria; 2.3 AMR in Food-Related Beneficial Microbes.
|
| 505 |
8 |
|
|a 2.4 Routes of Transmission of AMR Throughout the Food Chain2.4.1 Foods of Animal Origin; 2.4.2 Foods of Nonanimal Origin; 2.4.3 Primary Production and Food Processing Environments and Food Processing Technologies; 2.4.3.1 Role of Biocides in AMR Acquisition and Spread; 2.4.3.2 Food Processing Technologies and AMR; 2.5 Conclusions; References; 3 Penetrating the Bacterial Biofilm: Challenges for Antimicrobial Treatment; 3.1 Introduction; 3.1.1 Antimicrobial Treatment: In Desperate Need of a Wind of Change; 3.1.2 The Biofilm Lifestyle.
|
| 505 |
8 |
|
|a 3.2 How Biofilms Pose a Challenge to the Diffusion of Antibiotics3.2.1 Mass Transport Phenomena in Biofilms; 3.2.2 Dense Cell Clusters; 3.2.3 Binding Interactions Between Antibiotics and Matrix Constituents; 3.2.3.1 Physicochemical Binding to Matrix Polymers; 3.2.3.2 Inactivation of Antibiotics by Enzymes Present in the Biofilm Matrix; 3.3 How to Improve Antibiotic Delivery to Biofilm Cells?; 3.3.1 Interference With the Biofilm Structure; 3.3.2 Nanocarriers for Improved Delivery of Antibiotics in Biofilms; 3.3.2.1 Nanocarriers Protect Antibiotics From Interactions With Biofilm Components.
|
| 505 |
8 |
|
|a 3.3.2.2 Nanocarriers can be Designed to Increase Local Antibiotic Delivery3.3.2.3 Nanocarriers Can Shuttle Antibiotics Inside Bacterial Cells; 3.3.2.4 Responsive Nanoparticles: Antibiotic Release on Demand; 3.4 Conclusion; References; 4 Metal Nanoparticles for Microbial Infection; 4.1 Introduction; 4.2 Silver Nanoparticles for Microbial Infection; 4.2.1 Silver Nanoparticles Against Bacterial Infection; 4.2.2 Silver Nanoparticles Against Fungal Infection; 4.2.3 Silver Nanoparticles Against Viral Infection; 4.2.4 Silver Nanoparticles Against Protozoal Infection.
|
| 505 |
8 |
|
|a 4.2.5 Medical Applications of Silver Nanoparticles4.3 Copper Nanoparticles for Microbial Infection; 4.3.1 Copper Nanoparticles Against Bacterial Infection; 4.3.2 Copper Nanoparticles Against Fungal Infection; 4.3.3 Medical Applications of Copper Nanoparticles; 4.4 Gold Nanoparticles for Microbial Infection; 4.4.1 Gold Nanoparticles for Therapeutic Intervention; 4.4.2 Gold Nanoparticles for Antimicrobial Drug Delivery; 4.4.3 Gold Nanoparticles for Photodynamic Therapy; 4.4.4 Gold Nanoparticles for Photothermal Treatment; 4.4.5 Gold Nanoparticles for Diagnostic Applications.
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 650 |
|
0 |
|a Antibiotics.
|
| 650 |
|
2 |
|a Anti-Bacterial Agents
|0 (DNLM)D000900
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Antibiotics.
|2 fast
|0 (OCoLC)fst00810420
|
| 700 |
1 |
|
|a Boukherroub, Rabah.
|
| 700 |
1 |
|
|a Szunerits, Sabine.
|
| 700 |
1 |
|
|a Drider, Djamel.
|
| 776 |
0 |
8 |
|i Print version:
|t Functionalized Nanomaterials for the Management of Microbial Infection.
|d Amsterdam : Elsevier, 2017
|z 9780323416252
|z 032341625X
|w (OCoLC)957746435
|
| 830 |
|
0 |
|a Micro & nano technologies.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/book/9780323416252
|z Texto completo
|
